雲南白藥(000538.SZ)擬斥7.3億港元認購萬隆控股可換股債
格隆匯10月15日丨雲南白藥(000538.SZ)公佈,2019年10月14日,公司與萬隆控股(00030.HK)簽署《可換股債券認購協議》。公司同意以7.3億港元為對價,認購萬隆控股兩年到期、年利率3%的可換股債券。此次認購前,公司持有萬隆控股約19.08億股股份,佔万隆控股發行股本29.59%,為萬隆控股的第一大股東,上述股份為公司通過對雲南白藥控股有限公司(“白藥控股”)的吸收合併,承繼白藥控股所持有的萬隆控股股份。公司董事長王明輝任萬隆控股董事會主席、執行董事,此次交易構成關聯交易。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.